2020 Vs 2026. Just 1 mg finasteride and No Minoxidil. 9/22/2026
Finasteride has helped maintain hair and slow down thinning since 2017, despite no regrowth or use of Minoxidil. The user is considering a hair transplant in the future and is cautious about trying Dutasteride due to concerns about side effects.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity What the Breezula Phase III results mean & realistic timeline
Breezula offers modest hair growth similar to finasteride and is expected to be available by late 2026. It is a safe alternative without hormonal side effects and works well with minoxidil.
community I think we should all keep an eye out for Pelage PP405. February 2025 will be interesting.
Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.
community Everything you ever wanted to know about Pelage Pharma's PP405: how it works and what to expect
PP405 may encourage earlier hair growth and slightly increase visible hair count but does not reverse hair follicle miniaturization in male pattern baldness. It does not address damage to the dermal papilla or broken Wnt signaling.
community For those 3+ years post hair transplant, how has your hair held up?
Hair transplants can maintain results if combined with medications like finasteride, minoxidil, or dutasteride. Without medication, hair loss may continue, and some users consider additional transplants.
community Hair Growth Caps and Helmets Research
Hair growth caps and helmets using low-level laser therapy (LLLT) show potential for treating androgenetic alopecia, but more research is needed. Users often combine these devices with treatments like minoxidil and finasteride for better results.
Related Research
6 / 6 results
research Comparative Study of effectiveness of low dose Oral Minoxidil vs Topical Minoxidil (5%) in Male Androgenetic Alopecia.
This study found that low-dose oral minoxidil was more effective than topical minoxidil in increasing hair density and patient satisfaction among men with androgenetic alopecia, with fewer local side effects and better compliance reported over six months.
research Low Dose Oral Minoxidil in Androgenetic Alopecia
In this randomized controlled trial, researchers found that a 2.5 mg daily dose of oral minoxidil was more effective than a 1 mg dose in improving hair growth parameters in patients with androgenetic alopecia over three months, with both doses being well tolerated.
research Using a Natural Clay Mineral as an Active Drug Carrier to Promote Hair Growth
This study found that a natural illite-based carrier could deliver minoxidil topically with preserved efficacy, minimizing solvent toxicity, and showed hair-growth-promoting activity via anti-inflammatory and pro-proliferative mechanisms in mice.
research Promises and Pitfalls of Regenerative Therapies for Androgenetic Alopecia: Platelet-Rich Plasma, Photobiomodulation, Stem Cells, and Exosomes
This study critically reviewed recent evidence (2020–2025) on treatments like platelet-rich plasma, photobiomodulation, stem cells, and exosomes for androgenetic alopecia, finding emerging but limited efficacy data and emphasizing the need for standardized protocols to enhance transparency and patient safety.
research PEGylated Flavonoid Aspasomes as a Brain-Targeted Nano-Vesicular Platform for Enhanced Neuroprotection in Stress-Induced Cognitive Dysfunction
This study found that PEGylated LUT-Aspasomes significantly improved neuroprotective effects in stressed rats, enhancing spatial memory, reducing depressive-like behavior, and preserving hippocampal architecture better than free luteolin. Additionally, it increased brain delivery and stability, suggesting potential for treating stress-related neurobehavioral disorders.
research Development and Evaluation of a Niosome-Integrated Microneedle System for Targeted Follicular Delivery of Ketoconazole in Alopecia Therapy
This study reports that a novel ketoconazole-loaded microneedle array significantly enhances drug delivery and retention in the skin, demonstrating improved hair growth in animal models, suggesting a promising treatment for androgenic alopecia that addresses current topical therapies' limitations.